178 related articles for article (PubMed ID: 18472976)
21. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
22. Treatment of the 5q- syndrome.
Fenaux P; Kelaidi C
Hematology Am Soc Hematol Educ Program; 2006; ():192-8. PubMed ID: 17124060
[TBL] [Abstract][Full Text] [Related]
23. Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.
Santini V; Almeida A; Giagounidis A; Skikne B; Beach CL; Weaver J; Tu N; Fenaux P
Leuk Lymphoma; 2020 Jun; 61(6):1475-1483. PubMed ID: 32064987
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Giagounidis AA; Germing U; Strupp C; Hildebrandt B; Heinsch M; Aul C
Ann Hematol; 2005 Sep; 84(9):569-71. PubMed ID: 15891887
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.
Pisani F; Orlandi G; Merola R
Case Rep Oncol; 2014 Jan; 7(1):277-84. PubMed ID: 24926257
[TBL] [Abstract][Full Text] [Related]
26. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory drugs in myelodysplastic syndromes.
Galili N; Raza A
Expert Opin Investig Drugs; 2006 Jul; 15(7):805-13. PubMed ID: 16787143
[TBL] [Abstract][Full Text] [Related]
28. Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q).
Kurtin SE; Ridgeway JA; Tinsley S
J Adv Pract Oncol; 2017; 8(7):721-728. PubMed ID: 30333934
[No Abstract] [Full Text] [Related]
29. Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
Al-Jafar HA; Al-Azmi S; Qassem JA; Hasan EA; Alduaij A
Case Rep Oncol; 2012 Sep; 5(3):586-91. PubMed ID: 23185164
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.
Adès L; Boehrer S; Prebet T; Beyne-Rauzy O; Legros L; Ravoet C; Dreyfus F; Stamatoullas A; Chaury MP; Delaunay J; Laurent G; Vey N; Burcheri S; Mbida RM; Hoarau N; Gardin C; Fenaux P
Blood; 2009 Apr; 113(17):3947-52. PubMed ID: 18987358
[TBL] [Abstract][Full Text] [Related]
31. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
[TBL] [Abstract][Full Text] [Related]
33. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Komrokji RS; Zeidan AM
J Blood Med; 2015; 6():1-16. PubMed ID: 25565910
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Shah SR; Tran TM
Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
[TBL] [Abstract][Full Text] [Related]
36. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G
BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
[TBL] [Abstract][Full Text] [Related]
38. Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.
Garcia-Manero G; Almeida A; Fenaux P; Gattermann N; Giagounidis A; Goldberg SL; Ozawa K; Weaver J; Santini V
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):213-219.e4. PubMed ID: 30770308
[TBL] [Abstract][Full Text] [Related]
39. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide for treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
